Amedisys price target lowered to $115 from $130 at Truist

Truist lowered the firm’s price target on Amedisys to $115 from $130 but keeps a Buy rating on the shares as part of a broader research note on Health Care names. The firm remains bullish across much of Health Care Services given attractive core demand, the ongoing shift to value, reasonable valuations and impacts on the system over the past few years that have further tipped the playing field in favor of scaled and high quality providers, even though it still sees some macro challenges around a potential recession, available labor, and inflation.